CVI Holdings’s Cellectar Biosciences CLRB Stock Holding History

CVI Holdings’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,535	Closed	-$284K	–	423
2022 Q4	$284K	Buy	+5,535	New	+$332K	0.04%	256
2020 Q3	–	Sell	-467	Closed	-$179K	–	90
2020 Q2	$179K	Buy	+467	New	+$196K	0.07%	54
2019 Q3	–	Sell	-353	Closed	-$231K	–	43
2019 Q2	$231K	Buy	+353	New	+$241K	0.27%	31

Other funds holding CLRB

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

1WM

1900 Wealth Management San Antonio, Texas $1.56B AUM 14.13% 1-Year Est. Return

CVI Holdings's CLRB Position: Q1 2023 in Review

CVI Holdings sold out of Cellectar Biosciences (CLRB) in Q1 2023, closing a stake of 5,535 shares — an estimated $284K sold.

CVI Holdings first reported a position in CLRB in Q2 2019 and held it in 3 quarters. The position peaked at $284K in Q4 2022. 19 funds tracked by Wall St. Rank hold CLRB as of Q1 2023.

CVI Holdings reported no remaining Cellectar Biosciences position as of Q1 2023 after selling out during the quarter.
CVI Holdings sold 5,535 Cellectar Biosciences shares in Q1 2023, an estimated $284K.
CVI Holdings first reported a position in Cellectar Biosciences in Q2 2019 and held it in 3 quarters.
CVI Holdings's Cellectar Biosciences position peaked at $284K in Q4 2022.
19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2023.

Based on CVI Holdings's 13F filing for Q1 2023, filed 16 May 2023.